Cytokine pathway disruption in a mouse model of schizophrenia induced by Munc18-1a overexpression in the brain

Journal of Neuroinflammation

David Sulzer¹  J Javier Meana³  Jorge E Ortega³  Carolina Cebrián¹  Itziar Gil-Pisa² 

[1] Department of Neurology, Columbia University Medical Center, 710 W, 168th Street, New York, NY 10032, USA;Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barrio Sarriena s/n, Leioa, Bizkaia 48940, Spain;BioCruces Health Research Institute, Plaza de Cruces, Barakaldo, Bizkaia 48903, Spain

关键词: Cytokine;    Neuroinflammation;    Schizophrenia;    Animal model;    Munc18-1a;   

Others  :  1151208
DOI  :  10.1186/1742-2094-11-128

 received in 2014-03-12, accepted in 2014-06-26,  发布年份 2014

【 摘 要 】

Background

An accumulating body of evidence points to the significance of neuroinflammation and immunogenetics in schizophrenia, and an imbalance of cytokines in the central nervous system (CNS) has been suggested to be associated with the disorder. Munc18-overexpressing mice (Munc18-OE) have provided a model for the study of the alterations that may underlie the symptoms of subjects with schizophrenia. The aim of the present study was to elucidate the involvement of neuroinflammation and cytokine imbalance in this model.

Methods

Cytokines were evaluated in the cortex and the striatum of Munc18-OE and wild-type (WT) mice by enzyme-linked immunosorbent assay (ELISA). Protein levels of specific microglia and macrophage, astrocytic and neuroinflammation markers were quantified by western blot in the cortex and the striatum of Munc18-OE and WT mice.

Results

Each cytokine evaluated (Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-2 (IL-2) and CCL2 chemokine) was present at higher levels in the striatum of Munc18-OE mice than WT. Cortical TNF-α and IL-2 levels were significantly lower in Munc18-OE mice than WT mice. The microglia and macrophage marker CD11b was lower in the cortexes of Munc18-OE mice than WT, but no differences were observed in the striatum. Glial Fibrillary Acidic Protein (GFAP) and Nuclear Factor-kappaB (NF-κB)p65 levels were not different between the groups. Interleukin-1beta (IL-1β) and IL-6 levels were beneath detection limits.

Conclusions

The disrupted levels of cytokines detected in the brain of Munc18-OE mice was found to be similar to clinical reports and endorses study of this type for analysis of this aspect of the disorder. The lower CD11b expression in the cortex but not in the striatum of the Munc18-OE mice may reflect differences in physiological activity. The cytokine expression pattern observed in Munc18-OE mice is similar to a previously published model of schizophrenia caused by maternal immune activation. Together, these data suggest a possible role for an immune imbalance in this disorder.

【 授权许可】

   
2014 Gil-Pisa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Nathan C: Points of control in inflammation. Nature 2002, 420:846-852.
• [2]Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
• [3]Weizman R, Laor N, Wiener Z, Wolmer L, Bessler H: Cytokine production in panic disorder patients. Clin Neuropharmacol 1999, 22:107-109.
• [4]Kronfol Z, Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000, 157:683-694.
• [5]Banks WA, Moinuddin A, Morley JE: Regional transport of TNF-alpha across the blood–brain barrier in young ICR and young and aged SAMP8 mice. Neurobiol Aging 2001, 22:671-676.
• [6]Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T: Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990, 59:783-836.
• [7]Freidin M, Bennett MV, Kessler JA: Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc Natl Acad Sci USA 1992, 89:10440-10443.
• [8]Rothwell NJ, Luheshi G, Toulmond S: Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol Ther 1996, 69:85-95.
• [9]Haas HS, Schauenstein K: Neuroimmunomodulation via limbic structures–the neuroanatomy of psychoimmunology. Prog Neurobiol 1997, 51:195-222.
• [10]Muller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:1-33.
• [11]Mehler MF, Kessler JA: Cytokines in brain development and function. Adv Protein Chem 1998, 52:223-251.
• [12]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-IV-TR. New York: American Psychiatric Association; 2000.
• [13]Sperner-Unterweger B: Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs 2005, 65:1493-1520.
• [14]Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20:532-545.
• [15]Meyer U: Anti-inflammatory signaling in schizophrenia. Brain Behav Immun 2011, 25:1507-1518.
• [16]Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
• [17]Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
• [18]Johnson RD, Oliver PL, Davies KE: SNARE proteins and schizophrenia: linking synaptic and neurodevelopmental hypotheses. Acta Biochim Pol 2008, 55:619-628.
• [19]Voets T, Toonen RF, Brian EC, de Wit H, Moser T, Rettig J, Südhof TC, Neher E, Verhage M: Munc18-1 promotes large dense-core vesicle docking. Neuron 2001, 31:581-591.
• [20]Castillo MA, Ghose S, Tamminga CA, Ulery-Reynolds PG: Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry 2010, 67:208-216.
• [21]Toonen RF, Verhage M: Munc18-1 in secretion: lonely Munc joins SNARE team and takes control. Trends Neurosci 2007, 30:564-572.
• [22]Burgoyne RD, Barclay JW, Ciufo LF, Graham ME, Handley MT, Morgan A: The functions of Munc18-1 in regulated exocytosis. Ann N Y Acad Sci 2009, 1152:76-86.
• [23]Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR: Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 2009, 14:601-613.
• [24]Gil-Pisa I, Munarriz-Cuezva E, Ramos-Miguel A, Uriguen L, Meana JJ, Garcia-Sevilla JA: Regulation of munc18-1 and syntaxin-1A interactive partners in schizophrenia prefrontal cortex: down-regulation of munc18-1a isoform and 75 kDa SNARE complex after antipsychotic treatment. Int J Neuropsychopharmacol 2012, 15:573-588.
• [25]Garcia EP, McPherson PS, Chilcote TJ, Takei K, De Camilli P: rbSec1A and B colocalize with syntaxin 1 and SNAP-25 throughout the axon, but are not in a stable complex with syntaxin. J Cell Biol 1995, 129:105-120.
• [26]Swanson DA, Steel JM, Valle D: Identification and characterization of the human ortholog of rat STXBP1, a protein implicated in vesicle trafficking and neurotransmitter release. Genomics 1998, 48:373-376.
• [27]Uriguen L, Gil-Pisa I, Munarriz-Cuezva E, Berrocoso E, Pascau J, Soto-Montenegro ML, Gutierrez-Adan A, Pintado B, Madrigal JL, Castro E, Sánchez-Blázquez P, Ortega JE, Guerrero MJ, Ferrer-Alcón M, García-Sevilla JA, Micó JA, Desco M, Leza JC, Pazos Á, Garzón J, Meana JJ: Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. Transl Psychiatry 2013, 3:e221.
• [28]Braff DL, Geyer MA, Swerdlow NR: Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156:234-258.
• [29]O’Tuathaigh CM, Kirby BP, Moran PM, Waddington JL: Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr Bull 2010, 36:271-288.
• [30]Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 2009, 35:549-562.
• [31]Khasnavis S, Jana A, Roy A, Mazumder M, Bhushan B, Wood T, Ghosh S, Watson R, Pahan K: Suppression of nuclear factor-kappaB activation and inflammation in microglia by physically modified saline. J Biol Chem 2012, 287:29529-29542.
• [32]Luber-Narod J, Rogers J: Immune system associated antigens expressed by cells of the human central nervous system. Neurosc Lett 1988, 94:17-22.
• [33]García-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martínez-Cengotitabengoa M, Pina-Camacho L, Rodríguez-Jiménez R, Sáiz PA, Castro C, Lafuente A, Santabárbara J, González-Pinto A, Parellada M, Rubio G, García-Portilla MP, Micó JA, Bernardo M, Leza JC: Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis if schizophrenia. Schizophr Bull 2014, 40:376-387.
• [34]Roussos P, Katsel P, Davis KL, Giakoumaki SG, Siever LJ, Bitsios P, Haroutunian V: Convergent findings for abnormalities of the NF-kappaB signaling pathways in schizophrenia. Neuropsychopharmacol 2013, 38:533-539.
• [35]Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
• [36]Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
• [37]Davidson LL, Heinrichs RW: Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003, 122:69-87.
• [38]Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, Velligan DI: Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 2005, 25:60-69.
• [39]Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ: Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004, 110:243-256.
• [40]Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Keltner JR, Beal MF, Rosen BR, Jenkins BG: Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 1997, 38:389-398.
• [41]Pycock CJ, Kerwin RW, Carter CJ: Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980, 286:74-76.
• [42]Grace AA: Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41:1-24.
• [43]Deutch AY: The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992, 36:61-89.
• [44]Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF: Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002, 5:267-271.
• [45]Ingvar DH, Franzen G: Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 1974, 50:425-462.
• [46]Buchsbaum MS: The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr Bull 1990, 16:379-389.
• [47]Bullmore E, Brammer M, Williams SC, Curtis V, McGuire P, Morris R, Murray R, Sharma T: Functional MR imaging of confounded hypofrontality. Hum Brain Mapp 1999, 8:86-91.
• [48]Shi L, Fatemi SH, Sidwell RW, Patterson PH: Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003, 23:297-302.
• [49]Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M: Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006, 59:546-554.
• [50]Meyer U, Engler A, Weber L, Schedlowski M, Feldon J: Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience 2008, 154:701-709.
• [51]Banks WA: Blood–brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 2005, 11:973-984.
• [52]Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R: Low levels of circulating inflammatory cytokines–do they affect human brain functions? Brain Behav Immun 2002, 16:525-532.
• [53]Stanley AC, Lacy P: Pathways fro cytokine secretion. Physiol 2010, 25:218-229.
• [54]Lee M: Neurotransmitter and microglial-mediated neuroinflammation. Curr Protein Pept Sci 2013, 14:21-32.
• [55]Fineberg AM, Ellman LM: Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry 2013, 73:951-966.